ATP sulfurylase, from E. coli, catalyzes and conformationally couples the free energies of GTP hydrolysis and activated sulfate synthesis (reactions 1 and 2). The enzyme is the only example of a GTPase/target complex that couples the free energy of two chemical reactions. During the catalytic cycle, allosteric interactions between the active sites drive structural changes that control the progression of the individual reactions. These linking events result in an interdependence that fixes the stoichiometry of the reactions, and couples their free energies. The proposed studies are focused on these linking events and will establish paradigms for the allosteric interactions that occur in GTPase/target complexes, and the conformational coupling of free energy. ATP + SO(4) <-> APS + PPi (1) GTP + H(2)O <-> GDP + Pi + H(+) (2) In the second and final step of the sulfate activation pathway, the gamma-phosphoryl group of ATP is transferred to the 3'-hydroxyl of APS to form PAPS (reaction 3). ATP + APS <-> PAPS + ADP (3) PAPS is the only known sulfuryl group donor in metabolism. Sulfuryl transfer, much like phosphoryl transfer, is used extensively by the cell to regulate metabolite activity. In humans, the entire sulfate activating pathway is contained in a single enzyme, PAPS synthetase. This monomeric 73 kDa polypeptide catalyzes reactions 1 and 3 and channels APS between its active-sites. The human PAPS synthetase has been expressed and purified to homogeneity in the principal investigator's laboratory. Structures of channeling systems are rare and have revealed the amazing architecture that these enzymes use to shunt substrates between their active sites. PAPS synthetase promises to be one of those systems. Crystals of PAPS synthetase have been obtained that diffract to 2.8 angstroms. The existing paradigms suggest that channeling will require extensive allosteric interactions between active sites of PAPS synthetase. Dr. Leyh will initiate a structural and functional characterization of this fascinating system.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM054469-12
Application #
6519757
Study Section
Biochemistry Study Section (BIO)
Program Officer
Jones, Warren
Project Start
1995-09-02
Project End
2004-03-31
Budget Start
2002-04-01
Budget End
2003-03-31
Support Year
12
Fiscal Year
2002
Total Cost
$289,694
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Biochemistry
Type
Schools of Medicine
DUNS #
009095365
City
Bronx
State
NY
Country
United States
Zip Code
10461
Wang, Ting; Cook, Ian; Falany, Charles N et al. (2014) Paradigms of sulfotransferase catalysis: the mechanism of SULT2A1. J Biol Chem 289:26474-80
Rodriguez, Sofia B; Leyh, Thomas S (2014) An enzymatic platform for the synthesis of isoprenoid precursors. PLoS One 9:e105594
Cook, Ian; Wang, Ting; Almo, Steven C et al. (2013) The gate that governs sulfotransferase selectivity. Biochemistry 52:415-24
Leyh, Thomas S; Cook, Ian; Wang, Ting (2013) Structure, dynamics and selectivity in the sulfotransferase family. Drug Metab Rev 45:423-30
Jing, Chaoran; Cornish, Virginia W (2013) Design, synthesis, and application of the trimethoprim-based chemical tag for live-cell imaging. Curr Protoc Chem Biol 5:131-55
Pinto, Rachel; Leotta, Lisa; Shanahan, Erin R et al. (2013) Host cell-induced components of the sulfate assimilation pathway are major protective antigens of Mycobacterium tuberculosis. J Infect Dis 207:778-85
Cook, Ian; Wang, Ting; Falany, Charles N et al. (2013) High accuracy in silico sulfotransferase models. J Biol Chem 288:34494-501
Cook, Ian; Wang, Ting; Almo, Steven C et al. (2013) Testing the sulfotransferase molecular pore hypothesis. J Biol Chem 288:8619-26
Cook, Ian; Wang, Ting; Falany, Charles N et al. (2012) A nucleotide-gated molecular pore selects sulfotransferase substrates. Biochemistry 51:5674-83
Rohn, Katie Jo; Cook, Ian T; Leyh, Thomas S et al. (2012) Potent inhibition of human sulfotransferase 1A1 by 17ýý-ethinylestradiol: role of 3'-phosphoadenosine 5'-phosphosulfate binding and structural rearrangements in regulating inhibition and activity. Drug Metab Dispos 40:1588-95

Showing the most recent 10 out of 46 publications